KDM4B: A Non-Coding RNA Molecule in The NER Pathway (G23030)

Target Name: KDM4B

NCBI ID: G23030

KDM4B

KDM4B: A Non-Coding RNA Molecule in The NER Pathway

KDM4B, also known as Lysine-specific demethylase 4B (isoform 1), is a gene that encodes a protein located in the nucleotide excision repair (NER) pathway. NER is a critical process that helps repair damaged DNA in the human body, and it is often impaired in various diseases, including cancer.

KDM4B is a non-coding RNA molecule that functions as a key player in the NER pathway. It is composed of 215 amino acid residues and has a calculated molecular mass of 23.1 kDa. KDM4B is primarily localized to the cytoplasm of the cell and is involved in the repair of a specific type of DNA damage, known as a double-strand break.

KDM4B functions by using a unique mechanism to remove a type of DNA damage called a double-strand break. During DNA replication, the two strands of the double-strand DNA are separated and act as a template for the polymerase to synthesize a new complementary strand. However, if the replication process goes wrong, such as due to a double-strand break, the repair process is not straightforward. The KDM4B protein provides a mechanism to remove this type of damage and repair the double-strand break in the NER pathway.

KDM4B has been shown to play a critical role in various cellular processes, including cell growth, apoptosis, and DNA replication. It has been shown to regulate cell cycle progression, apoptosis, and cell survival in various cell types, including cancer cells.

KDM4B has also been shown to be a potential drug target in various diseases. For example, KDM4B has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting KDM4B may be a promising strategy for the development of new cancer therapies.

In addition to its potential as a drug target, KDM4B has also been shown to be a potential biomarker for various diseases. For example, KDM4B has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that measuring KDM4B levels in cancer cells or tissues may be a promising strategy for the detection and diagnosis of these diseases.

Overall, KDM4B is a non-coding RNA molecule that plays a critical role in the NER pathway and has been shown to function as a potential drug target and biomarker in various diseases. Further research is needed to fully understand the mechanisms of KDM4B and its potential as a drug and biomarker.

Protein Name: Lysine Demethylase 4B

Functions: Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Only able to demethylate trimethylated H3 'Lys-9', with a weaker activity than KDM4A, KDM4C and KDM4D. Demethylation of Lys residue generates formaldehyde and succinate (PubMed:16603238, PubMed:28262558). Plays a critical role in the development of the central nervous system (CNS)

The "KDM4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets